tablets Amlessa are shown in arterial hypertension and/or coronary heart disease (if treatment perindoprily and amlodipiny is necessary).

Structure

Active ingredients: a perindoprila it is grated - butylamine and amlodipin;

1 tablet contains 4 mg of a perindopril is grated - to butylamine (that corresponds 3.34 mg of a perindopril) and 5 ​​ by mg of an amlodipin (that corresponds to 6.935 mg of an amlodipin besilat), or;

4 mg of a perindopril it is grated - to butylamine (that corresponds 3.34 mg of a perindopril) and 10 mg of an amlodipin (that corresponds to 13.870 mg of an amlodipin besilat), or;

8 mg of a perindopril it is grated - to butylamine (that corresponds 6.68 mg of a perindopril) and 5 ​​ by mg of an amlodipin (that corresponds to 6.935 mg of an amlodipin besilat), or;

8 mg of a perindopril it is grated - to butylamine (that corresponds 6.68 mg of a perindopril) and 10 mg of an amlodipin (that corresponds to 13.870 mg of an amlodipin besilat);

Excipients: cellulose microcrystalline starch corn; starch sodium; Calcii chloridum, hexahydrate; Natrii hydrocarbonas; silicon dioxide colloidal stearate of magnesium.

Contraindication

• hypersensitivity to active ingredients (either to the APF any other inhibitors, or to dihydropyridine derivatives) or to excipient;
• Quincke's disease in the anamnesis connected with the previous treatment by APF inhibitors;
• congenital or idiopathic Quincke's disease;
• heavy arterial hypotension;
• shock, including cardiogenic shock;
• obstruction of an exit from a left ventricle (for example, a stenosis of an aorta of heavy degree);
• heart failure after an acute myocardial infarction with an unstable hemodynamics;
• pregnancy or planning of pregnancy;
• simultaneous use with medicaments which contain active ingredient aliskiren, to patients with diabetes or a renal failure (glomerular filtration rate <60 ml/min. / 1.73 m ² );
• simultaneous use with sakubitrilom/valzartany;
• extracorporal methods of treatment which lead to contact of blood with negatively charged surfaces;
• considerable bilateral stenosis of renal arteries or stenosis of an artery of the only kidney.

with

with 1 tablet a day once which is desirable for accepting in the morning before food.

Tablet are not subject to the section. Range of dosing allows to pick up flexibly a ratio of components depending on clinical requirements. The dose should be selected individually for each patient taking into account indications for use, a course of the disease and indicators of arterial blood pressure.

Use of the fixed combination is not suitable

for initial therapy.

Maximum daily dose - 1 tablet Amlessa of 8 mg / 10 mg a day.

to

Feature of use

Pregnant

It is contraindicated during pregnancy.

children are not recommended to appoint

due to the lack of researches with the assistance of this group of patients.

Drivers

Is recommended to be careful, especially in an initiation of treatment.

Overdose

About cases of overdose was not reported.

Side effects

Most frequent side reactions at separate use of a perindopril and amlodipin are: hypostases, drowsiness, dizziness, a headache (especially in an initiation of treatment), a food faddism (dysgeusia), paresthesias, disorders of vision (including doubling), a ring in ears, palpitation, inflows, hypotension (and the related symptoms), short wind, cough, an abdominal pain, nausea, vomiting, dyspepsia, change of a rhythm of defecation, diarrhea, a constipation, an itching, rash, hypostasis of joints (hypostasis of anklebones), spasms soft muscles, increased fatigue, an asthenia.

Simultaneous use is contraindicated to

.

Aliskiren. At patients with diabetes, or patients with impaired renal function the risk of emergence of a hyperpotassemia, deterioration in function of kidneys and cardiovascular incidence and lethality increases.

Extracorporal methods of treatment. Extracorporal methods of treatment which lead to contact of blood with negatively charged surfaces, such as dialysis or haemo filtration with use of certain membranes with high hydraulic permeability (for example, polyacrylonitrile) and aferez lipoproteids of low density using a sulfate dextran, because of the increased risk of development of anaphylactoid reactions of heavy degree. In case of need performing such treatment it is necessary to consider the possibility of use of a dialysis membrane of other type or use of other class of antihypertensive drugs.

Sakubitril / valsartan. Simultaneous use of a perindopril with sakubitrily / valzartany is contraindicated as the simultaneous inhibition of a neprilizin and APF can lead to increase in risk of developing a Quincke's disease. It is necessary to begin use of a sakubitril / valsartan not earlier than in 36 hours after reception of the last dose of a perindopril. Therapy perindoprily should be begun not earlier than in 36 hours after reception of the last dose of a sakubitril / valsartan.

Storage conditions

to Store

at a temperature not above 30 °C in original packing.

to Store

out of children's reach.

Expiration date - 3 years.